~ KEVEYIS® (dichlorphenamide) Fourth Quarter and Full-Year 2017 Revenue of $3.0 Million and $7.0 Million, Respectively ~ ~ Full-Year 2018 KEVEYIS Revenue Guidance of $16 to $19 Million ~ ~ MACRILEN™ (macimorelin) Product Launch on Track for Mid-2018 ~ ~ RECORLEV™ (levoketoconazole) Phase 3 Clinical Program Progressing with SONICS Top-line Results Expected in Mid-Year 2018 ~ […]
This post first appeared on Bloggerwave Inc. Is In The StockGuru Spotlight For October 22, 2010 | StockGuru SmallCap Alerts On Penny Stocks, please read the originial post: here
